NCT05001945

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Mineralys Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

Conditions

• Hypertension, Renal

Interventions

Type	Name	Description
DRUG	MLS-101 (Part I)	MLS-101 tablet(s) by mouth once or twice daily.
OTHER	Placebo (Part I)	Placebo tablet(s) by mouth once or twice daily.
OTHER	Placebo (Part II)	Placebo tablet(s) by mouth once daily.
DRUG	MLS-101 (Part II)	MLS-101 tablet(s) by mouth once daily.

Timeline

• Start date: 2021-07-01
• Primary completion: 2022-09-07
• Completion: 2022-10-07
• First posted: 2021-08-12
• Last updated: 2024-01-05
• Results posted: 2024-01-05

Locations

44 sites across 1 country: United States

Regulatory

• FDA-regulated drug study